Related Experiment Videos
The anthelminthic agent albendazole does not interact with p-glycoprotein
Gracia Merino1, Ana I Alvarez, Julio G Prieto
1Department of Physiology, Faculty of Veterinary, University of Leon, Leon, Spain.
Summary
Albendazole, an important antiparasitic drug, is not transported by or does not inhibit P-glycoprotein. This finding suggests that drug interactions involving P-glycoprotein are unlikely for albendazole.
Area of Science:
- Pharmacology
- Drug Metabolism
- Molecular Biology
Background:
- Albendazole is a crucial anthelminthic medication with known variable and low oral bioavailability.
- Understanding its interactions with drug transporters is vital for optimizing its clinical use.
Purpose of the Study:
- To investigate whether albendazole is a substrate or inhibitor of the P-glycoprotein (P-gp) efflux transporter.
- To assess the clinical relevance of P-glycoprotein in albendazole disposition.
Main Methods:
- In vitro studies using LLC-PK1, L-MDR1, and Caco-2 cell lines to evaluate albendazole transport and its effect on digoxin transport.
- In vivo studies utilizing P-glycoprotein-deficient (mdr1a/1b(-/-)) and wild-type mice to assess tissue distribution after intravenous albendazole administration.
Main Results:
- Albendazole demonstrated similar transport rates in both directions across LLC-PK1 and L-MDR1 cells, indicating it is not a P-gp substrate.
- Albendazole did not inhibit digoxin transport in Caco-2 cells, and P-gp inhibitors did not affect albendazole transport.
- In vivo studies showed comparable tissue distribution of albendazole in P-gp-deficient and wild-type mice.
Conclusions:
- Albendazole is neither a substrate nor an inhibitor of P-glycoprotein.
- Clinical interactions between albendazole and P-glycoprotein substrates or inhibitors are unlikely to be significant.